ReviewMolecular therapy : the journal of the American Society of Gene Therapy2025
Oncolytic HSV and cancer drug interactions: Current clinical status and future directions.
Review in Molecular therapy : the journal of the American Society of Gene Therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Development and preclinical evaluation of a decoy DLL4-encoding oncolytic HSV-1 for high-grade glioma.Oncogene · 2026Article
- Illuminating the path to oncolysis: rise of microbial phototherapy.Journal of nanobiotechnology · 2026Review
- Oncolytic Virotherapy in Solid Tumors: A Current Review.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- Review
- Oncolytic adenoviruses in bladder and kidney cancers: emerging strategies and next frontiers.Frontiers in microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Oncolytic herpes simplex viruses (oHSVs) are engineered to target and replicate specifically in tumor cells, minimizing damage to normal tissues. This live virus biotherapy entails direct tumor cell killing followed by stimulation of antitumor immunity, leading to abscopal effects in untreated lesions. Currently, there are two clinically approved oHSV biotherapeutics: Imlygic, marketed by Amgen for the treatment of advanced melanoma in the United States and Europe, and Delytact, conditionally approved for recurrent brain tumors in Japan. Lessons learned from initial testing in patients have led to the development of second-generation viruses designed to improve tumor cytotoxicity and/or antitumor immune responses. Preclinical research has also uncovered numerous virus-drug interactions predicted to be synergistic. This has resulted in numerous clinical trials that are currently evaluating these second-generation viruses as single agents or in combination with other antineoplastic therapeutics. As of this review, there are more than 100 clinical trials evaluating their safety and efficacy. Here, we lay out a summary of oHSVs and the rationale behind various virus-drug combinations in clinical trials for patients with different malignancies. We provide a comprehensive review that details the underlying mechanisms of oHSV design and virus-drug interactions that form the basis of their clinical investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.